Quantification of the Aminosteroidal Non-Depolarizing Neuromuscular Blocking Agents Rocuronium and Vecuronium in Plasma with Liquid Chromatography-Tandem Mass Spectroscopy

Gutteck-Amsler, Ursula; Rentsch, Katharina

doi:10.1093/clinchem/46.9.1413

Cited by 28 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Blood samples were collected into heparin-containing tubes and then centrifuged at 3220×g for 10 min at 4°C. All plasma samples were added to 0.2 mL of 1-M monobasic sodium phosphate solution per each 1 mL of plasma to avoid hydrolysis of ROC [15,16]. Plasma samples were stored at −20°C until analysis.…”

Section: Clinical Protocolmentioning

confidence: 99%

The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries

Costa

Coelho

Lanchote

et al. 2017

Eur J Clin Pharmacol

View full text Add to dashboard Cite

Purpose Rocuronium (ROC) is a neuromuscular blocker mainly eliminated by biliary excretion dependent on organic anion transporting polypeptide 1A2 (OATP1A2) hepatocellular uptake. However, the influence of SLCO1A2 (gene encoding OATP1A2) genetic polymorphism on ROC pharmacokinetics was never described before. The objective of this work was to evaluate the influence of genetic polymorphisms of SLCO1A2 on the pharmacokinetics of rocuronium (ROC). Methods Patients undergoing elective surgeries under general anesthesia using rocuronium as a neuromuscular blocker were genotyped for SLCO1A2 polymorphisms in the coding region (41A>G, 382A>T, 404A>T, 502C>T, 516A>C, 559G>A, 830C>A, and 833delA) and in the promoter region (-1105G>A,-1032G>A,-715T>C,-361G>A, and-189_-188insA). Rocuronium pharmacokinetic parameters were estimated by non-compartmental analysis. Results None of the patients had heterozygous or homozygous variant of 404A>T, 382A>T, 502C>T, 833delA, 830C>A, 41A>G, and-715T>C. A linkage disequilibrium was found between-1105G>A and-1032G>A genotypes. Patients genotyped as-A or AA (n = 17) for SLCO1A2-189_-188InsA showed reduced total clearance of ROC compared to patients genotyped as −/− (n = 13) (151.6 vs 207.1 mL/min, p ≤ 0.05). The pharmacokinetics parameters of ROC were not significantly different between other SLCO1A2 genotypes. Conclusion SLCO1A2-189_-188InsA polymorphism is related to the reduced clearance of rocuronium in patients submitted to elective surgeries under general anesthesia. Trial registration NCT 02399397 (ClinicalTrials.gov)

show abstract

Section: Clinical Protocolmentioning

confidence: 99%

The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries

Costa

Coelho

Lanchote

et al. 2017

Eur J Clin Pharmacol

View full text Add to dashboard Cite

show abstract

“…The benzylisoquinolines and aminosteroids were analyzed by reversed-phase liquid chromatography electrospray ionization mass spectrometry. 22 All drugs were stabilized to avoid hydrolysis: 10 l echothiopate iodide (50 mg/ml, mivacurium) or 4 ml H 2 SO 4 (0.015 M atracurium, cisatracurium) were added immediately to 1 ml of the diluted benzylisoquinoline samples, and 200 l NaH 2 PO 4 (1 M) was added to 2 ml of the diluted aminosteroid samples. The samples were kept frozen (Ϫ20°C) until analysis.…”

Section: In Vivo Deliverymentioning

confidence: 99%

Different Patterns of Mast Cell Activation by Muscle Relaxants in Human Skin

Koppert¹,

Blunk²,

Petersen³

et al. 2001

Anesthesiology

View full text Add to dashboard Cite

show abstract

“…but they are also main degradation products of rocuronium (Blazewich et al, 2007). The analytical techniques for determination of rocuronium bromide and its main metabolites in biological samples presented in the literature included liquid chromatography-mass spectrometry (Cirimele et al, 2003;Gutteck-Amstel and Rentsch, 2000;Farenc et al, 2001;Fuchs-Buder et al, 2004;Sayer et al, 2004) and gas chromatography with mass spectrometry (Gao et al, 2001). There is only one published method for determination of rocuronium and its impurities in pharmaceutical preparation, which includes liquid chromatography with electrochemical detection (Blazewich et al, 2007).…”

Section: Determination Of Rocuronium Bromide By Hydrophilic Interactimentioning

confidence: 99%

Determination of Rocuronium bromide by hydrophilic interaction liquid chromatography (HILIC)

Nakov¹,

Petkovska²,

Ugrinova³

et al. 2001

Maced. Pharm. Bull.

View full text Add to dashboard Cite

A new method involving hydrophilic interaction liquid chromatography (HILIC) has been developed for determination of rocuronium bromide in presents of its main impurities (impurity A and impurity C), which are also its main degradation products, in solution for injection. The influence of the critical chromatographic parameters such as content of acetonitrile in the mobile phase, ionic strength and pH value of the buffer used in the mobile phase were investigated using the Design of experiments approach (DoE). The mechanism of retention of rocuronium bromide on bare silica column was also investigated. Optimal chromatographic conditions were obtained using mixture of acetonitrile and ammonium formate (107.5mM, pH 7.0) in ratio 90:10 as a mobile phase. The validation results have shown that the method is suitable for determination of rocuronium bromid in solution for injection.

show abstract

Quantification of the Aminosteroidal Non-Depolarizing Neuromuscular Blocking Agents Rocuronium and Vecuronium in Plasma with Liquid Chromatography-Tandem Mass Spectroscopy

Cited by 28 publications

References 6 publications

The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries

The SLCO1A2 -189_-188InsA polymorphism reduces clearance of rocuronium in patients submitted to elective surgeries

Different Patterns of Mast Cell Activation by Muscle Relaxants in Human Skin

Determination of Rocuronium bromide by hydrophilic interaction liquid chromatography (HILIC)

Contact Info

Product

Resources

About